{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid

• ChemBase编号: 591
• 分子式: C9H23NO7P2
• 平均质量: 319.228942
• 单一同位素质量: 319.09497534
• SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)CCN(CCCCC)C
• Canonical SMILES: CCCCCN(CCC(P(=O)(O)O)(P(=O)(O)O)O)C
• InChI: InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
• InChIKey: MPBVHIBUJCELCL-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid
• IUPAC传统名: ibandronate
• 商标名: Boniva; Bonviva; Bondronat
• 别名: (1-Hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyl)diphosphonic acid; Ibandronate sodium; Ibandronate sodium monohydrate; Ibandronic Acid; R484; ibandronate; Ibandronate; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID

登记号

• CAS号: 114084-78-5
• MDL号: MFCD00868772
• PubChem SID: 160964054; 46508134
• PubChem CID: 60852

理论计算性质

JChem

• Acid pKa: 0.6608223
• 质子受体: 8
• 质子供体: 5
• LogD (pH = 5.5): -4.524289
• LogD (pH = 7.4): -4.8642755
• Log P: -2.4814348
• 摩尔折射率: 71.1627 cm^3
• 极化性: 28.144053 Å^3
• 极化表面积: 138.53 Å^2
• 可自由旋转的化学键: 9
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 0.26
• LOG S: -1.38
• 溶解度: 1.34e+01 g/l

分子性质

理化性质

• 溶解度: Freely soluble
• 疏水性(logP): -2.1

产品相关信息

• 纯度: 95+%

详细说明

DrugBank - DB04635

Drug information: experimental

DrugBank - DB00710

• Drug Groups: approved; investigational
• Description: Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
• Indication: For the treatment and prevention of osteoporosis in postmenopausal women.
• Pharmacology: Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
• Toxicity: LD₅₀ = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.
• Affected Organisms: Humans and other mammals
• Biotransformation: No evidence of ibandronate being metabolized in humans.
• Absorption: Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
• Half Life: 10-60 hours
• Protein Binding: 90.9 to 99.5% over an ibandronate concentration range of 2 to 10 ng/mL
• Elimination: Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces.
• Distribution: * 90 L
• Clearance: * 84 to 160 mL/min [IV administration]
• References: Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

参考文献

• Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. Pubmed